Details

Autor(en) / Beteiligte

• Wagan, Abrar Ahmed
• Chandio, Sultan Ahmed
• Surahyo, Paras

Titel

Premature Ejaculatory Dysfunction in Rheumatoid Arthritis (PED-RA Study)

Ist Teil von

• Pakistan journal of medical sciences, 2022-12, Vol.38 (8), p.2131-2136

Ort / Verlag

Pakistan: Knowledge Bylanes

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Nexis Uni

Beschreibungen/Notizen

• Objective: To determine the frequency of premature ejaculatory dysfunction in rheumatoid arthritis patients. Methods: After approval from IRB, cross sectional study was conducted from November 1st, 2020 to August 1st, 2021 at Department of Rheumatology, Indus Medical College, Pakistan. RA patients were included, written and informed consents were taken. Demographic data was noted and detailed history and examination was carried out. Each participant BMI and Blood pressure was measured. Afterward 5-ml of blood was drawn by a trained phlebotomist for CBC, ESR, fasting blood sugar levels, HBs Ag and anti HCV Antibody test. DAS-28 Calculator was used for RA clinical activity. Premature ejaculation diagnostic tool was used for the assessment of premature ejaculation. Results: Total 168 patients with mean age 32.27 (SD=±9.49) and mean disease duration of 6.35 (SD=±3.95) years were included,. Prevalence of premature ejaculation dysfunction was (44.6%), with mean PED of score 9.17 (SD=±5.23). Hypertension, HCV, Hakeem medications, use of DMARDS had positive association while High BMI and higher DAS-28 has negative association with PED (p<0.05). Conclusion: There is high prevalence of PED in RA, it needs proper evaluation, treatment and urgent research is needed to know more about it. doi: https://doi.org/10.12669/pjms.38.8.5698 How to cite this:Wagan AA, Chandio SA, Surahyo P. Premature Ejaculatory Dysfunction in Rheumatoid Arthritis (PED-RA Study). Pak J Med Sci. 2022;38(8):---. doi: https://doi.org/10.12669/pjms.38.8.5698 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.